AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 146 min read$PSTV

Cerenome Reports Second Quarter 2026 Financial Results and Business Update

CERENOME, INC. (PSTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerenome Reports Second Quarter 2026 Financial Results and Business Update HOUSTON, August 14, 2026 – Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted th

Original reporting
SEC EDGAR 8-K
Published Aug 14, 2026, 8:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PSTV
Neutral
medium confidence
Mentioned
$PSTV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PSTVNeutralMed
01

Why it matters

The market will likely reprice the probability-weighted path to 2026 milestones (trial enrollment completion, FDA end-of-phase-2 meeting timing, and payer coverage expansion) against ongoing cash burn and operating losses.

02

Market read

Fresh quarter financials (cash and losses) plus affirmed clinical and commercial milestones can influence near-term valuation and funding-risk perception for PSTV.

03

What to watch

Traders may underweight the significance of the cash balance change and the lack of new, time-critical clinical readouts in this quarter.

Relevance 7/10Novelty 6/10Timing: after-hours filing today, before next clinical/commercial updates

Background

The filing is an Item 2.02 8-K with Q2 2026 financial results and business updates for Cerenome, including a recent rebranding and ongoing REYOBIQ and CNSide initiatives.

Company-level read

Ticker impact

$PSTVNeutralMedium confidence
Context

Cerenome (PSTV) reported Q2 2026 results, cash of $8.6M, and affirmed 2026 milestones for REYOBIQ and CNSide commercial rollout.

Expected impact

Likely modest, with focus on cash runway and the credibility/timing of 2026 enrollment and commercial payer coverage milestones.

Evidence & confidence

This is a primary SEC filing with new quarter financials and milestone affirmations, but it does not include a decisive binary catalyst like trial readout, approval, or a financing event.

Market effects

Sector

Adds datapoints on CNS oncology development and diagnostic commercialization progress, relevant to small-cap biotech sentiment and payer-coverage expectations.

Regional

Limited, as the filing is company-specific with no broader regional policy or supply-chain shock.

Global

Low, as the news is primarily US clinical trials and US reimbursement/diagnostics execution.

Counterpoint

What could challenge this read

Despite milestone affirmations, the company’s operating loss widened and cash remains modest, so execution risk may outweigh the incremental progress described.

Key entities

  • issuer
    Cerenome, Inc.

    Nasdaq-listed CNS oncology company reporting Q2 2026 financials and affirming 2026 milestones for REYOBIQ and CNSide.

  • product_candidate
    REYOBIQ (rhenium Re186 obisbemeda)

    Lead targeted CNS radiotherapy in ReSPECT-LM, ReSPECT-GBM, and ReSPECT-PBC trials.

  • diagnostics_platform
    CNSide CSF Assay Platform

    Commercial laboratory-developed CSF testing platform with payer coverage and billing infrastructure progress.

  • grantor
    CPRIT

    Texas cancer research institute funding REYOBIQ development; grant revenue referenced in Q2 results.

  • regulator
    FDA

    End-of-Phase 2 meeting referenced for ReSPECT-GBM after Q1 2027 data.

Read at source← All news

Related articles

OCT 8
$HELEHighAI 9/10

Helen of Troy raises profit outlook after second-quarter earnings beat

Helen of Troy (HELE) reported Q2 adjusted EPS of $0.79, up from $0.59 a year earlier, and raised its fiscal 2027 profit outlook. Revenue increased 2.1% to $440.9M, with growth in Home & Outdoor offsetting a decline in Beauty & Wellness. Adjusted EBITDA rose to $49.4M, lifting the margin to 11.2% from 8.4%. The company also raised its adjusted EBITDA and operating cash flow forecasts. Shares jumped over 20% in premarket trading.

finance.yahoo.com2 min
OCT 8
$XAIRMed

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last ye

SEC EDGAR 8-K3 min
OCT 8
$NKEMedAI 8/10

Nike Guided Earnings Below Its Dividend. Here’s What Backs the CFO’s Payout Pledge

Nike (NKE) guided fiscal 2027 adjusted EPS to $1.15-$1.35, below its $1.64 annual dividend. Shares closed at $34.36, yielding 4.8%. CFO David Denton pledged to maintain and grow the dividend, despite trailing normalized EPS of $1.58. Nike had $8.4B in cash and $2.18B in fiscal 2026 free cash flow, covering the $2.4B annual dividend cost. Analysts' target prices range from $27.50 (Berenberg) to ~$98.

finance.yahoo.com2 min